Notice of intention to make a decision on a facility licence application - Application No. A0309

Overview

The Australian Radiation Protection and Nuclear Safety Act 1998 was enacted to provide a legislative framework for the protection of the public, workers, and the environment from the harmful effects of ionising radiation, and for the safe use of nuclear substances and radiation-producing equipment. The Act was introduced to address the need for a robust regulatory system to govern the use of radioactive materials and nuclear substances, ensuring safety and compliance with international standards. Enacted by the Australian Parliament, the policy objective of the Act is to maintain and enhance the health and safety of people and the environment by regulating the use of radiation and nuclear substances in Australia. The Act provides the basis for the creation of the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), which is responsible for administering and enforcing the Act and its regulations. The Act also outlines the processes for licensing and the ongoing regulation of facilities and activities involving radiation and nuclear substances.

Scope and Application

The Australian Radiation Protection and Nuclear Safety Act 1998 applies to any person or entity involved in the use, production, or handling of radioactive substances and nuclear material in Australia. This Act extends to all states and territories, ensuring a consistent approach to the regulation of radiation and nuclear safety across the nation. The Act governs the licensing of facilities and activities that involve radiation and nuclear substances, ensuring that they comply with safety standards to protect public health and the environment. The Act applies to the proposed ANSTO Nuclear Medicine Molybdenum-99 Facility, a nuclear installation operated by ANSTO Nuclear Medicine Pty Ltd, which is situated at Lucas Heights Science and Technology Centre in Menai, New South Wales. The CEO of the Australian Radiation Protection and Nuclear Safety Agency, pursuant to sub-regulation 40(2) of the Australian Radiation Protection and Nuclear Safety Regulations 1999, intends to make a decision on the facility licence application under section 32 of the Act. The application process involves a thorough assessment of the facility’s compliance with the Act’s requirements, ensuring it meets the necessary safety and regulatory standards. The Act’s scope is broad and includes the establishment of safety standards, licensing requirements, and oversight mechanisms for all entities and activities involving radiation and nuclear substances in Australia.

Key Provisions

The Australian Radiation Protection and Nuclear Safety Act 1998, specifically section 32, empowers the Chief Executive Officer (CEO) of the Australian Radiation Protection and Nuclear Safety Agency to make decisions on applications for facility licences (s. 32). In this instance, the CEO intends to decide on Application No. A0309 by ANSTO Nuclear Medicine Pty Ltd, seeking a facility licence to operate a Nuclear Installation, the ANSTO Nuclear Medicine Molybdenum-99 Facility, at Lucas Heights Science and Technology Centre in Menai, New South Wales (s. 32, sub-reg. 40(2)). The Act imposes several obligations on the parties involved in the facility licence application process. Firstly, the applicant, ANSTO Nuclear Medicine Pty Ltd, must ensure that all necessary documentation and information are provided to the CEO in a timely manner. This includes detailed plans, safety measures, and compliance with relevant regulations (s. 32). The CEO, on the other hand, is required to review the application thoroughly, assess the risk to public health and safety, and consider any submissions from the public or relevant stakeholders before making a decision (s. 32, sub-reg. 40(2)). Breaches of the provisions under the Australian Radiation Protection and Nuclear Safety Act 1998 can lead to significant consequences. The Act includes provisions for offences and penalties, particularly under section 284, which covers offences related to radiation protection and nuclear safety. For instance, if the ANSTO Nuclear Medicine Pty Ltd fails to comply with the licence conditions or regulations, it may be subject to penalties, including fines of up to $1,080,000 for a company and imprisonment for up to 10 years for individuals (s. 284). Furthermore, non-compliance with the facility licence application process or failure to provide accurate information can also result in administrative penalties, including revocation of the licence or refusal of the application. In summary, the CEO’s decision on the facility licence application by ANSTO Nuclear Medicine Pty Ltd is a critical step under section 32 of the Act, with specific obligations placed on both the applicant and the CEO. Failure to adhere to the requirements and regulations can result in severe civil and criminal penalties, underscoring the importance of compliance with the Act’s provisions.